This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Top Hedge Fund Stock Buys

10. Genzyme

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Global biotech major Genzyme (GENZ) attracted $1.1 billion worth of hedge fund purchases in the fourth quarter. John Paulson was a big buyer, snapping up an additional 4.93 million shares to take his total holding to over 6 million. SAC Capital, Eton Park and Farallon Capital were other prominent buyers.

After nine months of negotiation, Sanofi- Aventis (SNY) agreed to buy Genzyme (GENZ) for $20.1 billion in cash, with additional payments possible depending upon the performance of the latter's drugs. Shareholders will initially receive $74 per share and a potential $14 per share if drugs such as its multiple-sclerosis drug Lemtrada, Cerezyme and Fabrazyme, used to treat rare diseases, meet performance targets.

Clearly Paulson's bet on the deal going through paid off. It will be interesting to see the changes in positions in Genzyme in his next quarterly filing now that the terms of the deal are out, as it would likely reflect the hedge fund titan's expectations on the performance of Genzyme's drug pipeline.

Most sell-side analysts preferred to sit on the fence on that one, with 17 rating the stock a hold. Only three analysts rate the stock a buy.
2 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
APC $37.81 0.00%
LYB $76.46 0.00%
WMB $13.47 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs